# Lilly Expands Supply of Zepbound® (Tirzepatide) for Adults Living with Obesity ## Key Points: – Eli Lilly and Company introduces Zepbound® single-dose vials to enhance access for those with obesity. – The drug, also known as tirzepatide, has shown promising results in clinical trials for weight management. – The availability of Zepbound® aims to support individuals in achieving their weight loss goals. – This expansion of supply signifies a significant step towards addressing obesity-related health concerns. Eli Lilly and Company’s decision to introduce Zepbound® single-dose vials is a welcomed development for individuals struggling with obesity. The availability of this medication provides an additional avenue for those looking to manage their weight effectively. With the promising results demonstrated in clinical trials, Zepbound® offers hope to individuals seeking sustainable weight loss solutions. This initiative showcases Eli Lilly’s commitment to supporting the health and well-being of those affected by obesity. ### Contact Mindful Evolution today to explore personalized weight loss strategies and achieve your wellness goals. Our telehealth services are available in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia. Reach out to us at 954-639-9960 for a consultation. Weight Loss Disclaimer: Individual results may vary. It is essential to consult with a healthcare provider before starting any weight loss program or treatment.